 |
N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt |
|---|---|
| Trade Name | |
| Orphan Indication | Epidermal growth factor receptor mutation-positive non-small cell lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2014-09-04 00:00:00 |
| Sponsor | AstraZeneca Pharmaceuticals LP;P. O. Box 8355, 1800 Concord Pike;Wilmington, DE, 19803-8355 |
